Journal of Korean Traditional Oncology (대한암한의학회지)

Korean Association of Traditional Oncology (대한암한의학회)
권호 표지
DOI QR코드

DOI QR Code

A Literature Review of Management for Opioid-Induced Constipation in Cancer Patients

암 환자의 마약성 진통제로 인한 변비 치료법에 대한 문헌고찰

  • Yoon, Jee-Hyun (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Kim, Eun Hye (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Lee, Jee Young (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Yoon, Seong Woo (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong)
  • 윤지현 (강동경희대학교한방병원 한방암센터 한방내과) ;
  • 김은혜 (강동경희대학교한방병원 한방암센터 한방내과) ;
  • 이지영 (강동경희대학교한방병원 한방암센터 한방내과) ;
  • 윤성우 (강동경희대학교한방병원 한방암센터 한방내과)
  • Received : 2020.11.19
  • Accepted : 2020.12.17
  • Published : 2020.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Constipation is the most common adverse effect of opioid analgesic therapy in cancer patients. This can be associated with physical and emotional distress to cancer patients. The purpose of this study is to review the standard and alternative interventions of the management for opioid-induced constipation (OIC). Methods: The studies were searched from databases, including Pubmed, Google scholar, KISS, NDSL, and OASIS. The main search terms included such as constipation, opioid, opioid-induced constipation, cancer, management, herb, and acupuncture. Results: The prevention and usual care of constipation is a key tool for the management of OIC. Also, prophylactic laxatives starting concurrently with opiates helped to prevent developing constipation. Peripherally acting μ-opioid receptor antagonists (PAMORAs) significantly reduced OIC and well-tolerated. In addition, acupuncture, herb medicines, and interferential current or transcutaneous electrical nerve stimulation to acupoints had effectiveness in reducing constipation. Conclusion: Preliminary data indicate that PAMORAs and Traditional Korean Medicine may be considered as the management of unresolved OIC. However, due to the limited articles, more systematic and rigorous clinical trials are needed.

Keywords

Acknowledgement

본 연구는 한국보건산업진흥원을 통해 보건복지부 「한의약선도기술개발사업」의 재정 지원을 받아 수행된 연구임(과제고유번호: HB16C0067).

References

  1. Kim JH, Song H, Lee GW, Kang JH. Opioid withdrawal symptoms after conversion to oral oxycodone/naloxone in advanced cancer patients receiving strong opioids. Korean J Hosp Palliat Care 20(2):131-135, 2017 https://doi.org/10.14475/kjhpc.2017.20.2.131
  2. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin 21(10):1555-1566, 2005 https://doi.org/10.1185/030079905X65321
  3. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D. Management of opioid side effects in cancer-related and chronic noncancer pain-A systematic review. J Pain 4(5):231-256, 2003 https://doi.org/10.1016/S1526-5900(03)00556-X
  4. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician 11(2):S105-S120, 2008
  5. Hong KS, Jung KW, Lee TH, Lee BE, Park SY, Shin JE, Kim SE, Park KS, Choi SC. Current issudes on the treatment of chronic constipation. Korean J Gastroentero 64(3):148-153, 2014 https://doi.org/10.4166/kjg.2014.64.3.148
  6. Shin JE. Understanding the Rome IV : Functional constipation and anorectal disorders. Korean J Med 92(4):372-381, 2017 https://doi.org/10.3904/kjm.2017.92.4.372
  7. Boland JW, Boland, EG. Pharmacological therapies for opioid induced constipation in adults with cancer. BMJ 358:J3313. 2017. DOI:10.1136/bmj.j3313
  8. Shin JE. Understanding the Rome IV : Functional constipation and anorectal disorders. Korean J Med 92(4):372-381, 2017 https://doi.org/10.3904/kjm.2017.92.4.372
  9. Larkin PJ, Cherny NI, La Carpia D, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol 29(4):111-125, 2018
  10. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag 5(3):137-144. 2009 https://doi.org/10.5055/jom.2009.0014
  11. Gatti A, Sabato AF. Management of Opioid-Induced Constipation in Cancer Patients. Clin Drug Investig 32:293-301, 2012 https://doi.org/10.2165/11598000-000000000-00000
  12. LoCasale RJ, Datto CJ, Margolis MK, Tack J, Coyne KS. The impact of opioid-induced constipation among chronic pain patients with sufficient laxative use. Int J Clin Pract. 69(12):1448-1456, 2015 https://doi.org/10.1111/ijcp.12718
  13. Jeon HH, Park HJ. Diagnosis and treatment of constipation. Korean J Med 83(5):568-579, 2012 https://doi.org/10.3904/kjm.2012.83.5.568
  14. Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum 44(8):1201-1209, 2001 https://doi.org/10.1007/BF02234645
  15. Agra Y, Sacristan A, Gonzalez M, Ferrari M, Portugues A, Calvo MJ. Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J Pain Symptom Manage 15(1):1-7, 1998 https://doi.org/10.1016/S0885-3924(97)00276-5
  16. Ahmedzai, SH, Boland J. Constipation in people prescribed opioids. BMJ Clin Evid 2010:2407, 2010
  17. Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med 11(4):575-581, 2008 https://doi.org/10.1089/jpm.2007.0178
  18. Pitlick M, Fritz D. Evidence about the pharmacological management of constipation, part 2: implications for palliative care. Home Healthc Nurse 31(4):207-218, 2013 https://doi.org/10.1097/NHH.0b013e3182885dd8
  19. Selby W, Corte C. Managing constipation in adults. Aust Prescr 33:116-119, 2010 https://doi.org/10.18773/austprescr.2010.058
  20. Twycross R, Sykes N, Mihalyo M, Wilcock A. Stimulant laxatives and opioid-induced constipation. J Pain Symptom Manage 43(2):306-313, 2012 https://doi.org/10.1016/j.jpainsymman.2011.12.002
  21. Larkin PJ, Sykes NP, Centeno C, Ellershaw JE, Elsner F, Eugene B, Zuurmond WWA. The management of constipation in pallative care: Clinical practice recommendations. Palliat Med 22(7):796-807, 2008 https://doi.org/10.1177/0269216308096908
  22. National Comprehensive Cancer Network. NCCN practice guidelines [Internet]. Version 1. Fort Washington, PA: National Comprehensive Cancer Network; c2020. 2020 for Pallative care [cited 2020 Oct 19]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf
  23. Siemens W, Becker G. Methylnaltrexone for opioid-induced constipation : Review and meta-analyses for objective plus subjective efficacy and safety outcomes. Ther Clin Risk Manag 12:401-412, 2016 https://doi.org/10.2147/TCRM.S80749
  24. Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, Von Gunten CF, Israel RJ. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 35(5):458-468, 2008 https://doi.org/10.1016/j.jpainsymman.2007.12.005
  25. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid induced constipation in advanced illness. N Engl J Med 358(22):2332-2343, 2008 https://doi.org/10.1056/NEJMoa0707377
  26. Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, Zhukovsky DS, Stephenson R, Portenoy R, Stambler N, Israel R. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 7(1):39-46, 2009
  27. Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. J Palliat Med 18(7):593-600, 2015 https://doi.org/10.1089/jpm.2014.0362
  28. Mori M, Yongli J, Kumar S, Ashikaga T, Ades S. Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study. Int J Clin Oncol 22:397-404, 2017 https://doi.org/10.1007/s10147-016-1041-6
  29. Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 154(9):1542-1550, 2013 https://doi.org/10.1016/j.pain.2013.04.024
  30. Chey WD, Webster L, Sostek M, Lappalainen J, Barkder PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 370:2387-2396, 2014 https://doi.org/10.1056/NEJMoa1310246
  31. Katakami N, Oda K, Tauchi K, Nakata K, Shinozaki K, Yokota T, Suzuki Y, Narabayashi M, Boku N. Phase IIb, randomized, double blind, placebo-controlled study of naldemedine for the treatment of opioid induced constipation in patients with cancer. J Clin Oncol 35:1921-1928, 2017 https://doi.org/10.1200/JCO.2016.70.8453
  32. Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract 65:472-478, 2011 https://doi.org/10.1111/j.1742-1241.2011.02634.x
  33. Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR. Eur J Pain 21:1528-1537, 2017 https://doi.org/10.1002/ejp.1054
  34. Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study. Eur J Pain 21:1485-1494, 2017 https://doi.org/10.1002/ejp.1050
  35. Chung VC, Wu X, Lu P, Hui EP, Zhang Y, Zhang AL, Lau AY, Zhao J, Fan M, Ziea ET, Ng BF, Wong SY, Wu JC. Chinese Herbal Medicine for Symptom Management in Cancer Palliative Care: Systematic Review And Meta-analysis. Medicine (Baltimore) 95(7):e2793, 2016. doi: 10.1097/MD.0000000000002793.
  36. Gao YL, Li LY, Li PW. Clinical study on the effectiveness of Yi-Qi-Run-Chang Method for opioids induced constipation. J Trad Chin Med Emergency 19(4);585-586, 2016
  37. Chen CM, Lin LZ, Zhang EX. Standardized treatment of Chinese medicine decoction for cancer pain patients with opioid-induced constipation: A multi-center prospective randomized controlled study. Chin J Integr Med 20(7):496-502, 2014 https://doi.org/10.1007/s11655-014-1864-9
  38. Zhang FL, Lin HS, He QY. Effect of electro-acupuncture in treating morphine sulfate caused constipation in tumor patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 29(10):922-925, 2009
  39. Zhu HD, Gong Z, Hu BW, Wei QL, Kong J, Peng CB. The efficacy and safety of transcutaneous acupoint interferential current stimulation for cancer pain patients with opioid-induced constipation: A prospective randomized controlled study. Integr Cancer Ther 17(2):437-443, 2018 https://doi.org/10.1177/1534735417734910
  40. Cai H, Zhou Q, Bao G, Kong X, Gong LY. Transcutaneous electrical nerve stimulation of acupuncture points enhances therapeutic effects of oral lactulose solution on opioid-induced constipation. J Int Med Res 47(12):6337-6348, 2019 https://doi.org/10.1177/0300060519874539
  41. Markland AD, Palsson O, Goode PS, Burgio KL, Busby-Whitehead J, Whitehead WE. Association of low dietary intake of fiber and liquids with constipation: evidence from the National Health and Nutrition Examination Survey. Am J Gastroenterol 108(5):796-803, 2013 https://doi.org/10.1038/ajg.2013.73
  42. Yang J, Wang HP, Zhou L, Xu CF. Effect of dietary fiber on constipation: A meta analysis. World J Gastroenterol 18(48):7378-7383, 2012 https://doi.org/10.3748/wjg.v18.i48.7378
  43. Lamas K, Lindholm L, Stenlund H, Engstrom B, Jacobsson C. Effects of abdominal massage in management of constipation-a randomized controlled trial. Int J Nurs Stud 46(6):759-767, 2009 https://doi.org/10.1016/j.ijnurstu.2009.01.007
  44. Park JU, Byun JI, Jung SH, Son IJ, Lee HS. Prophylactic laxative use and the compliance in relation to opioid-induced constipation. J Kor Soc Health-Syst Pharm 28(2):136-141, 2011 https://doi.org/10.32429/jkshp.2011.28.2.006
  45. Wickham RJ. Managing Constipation in Adults With Cancer. J Adv Pract Oncol 8(2):149‐161, 2017
  46. Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, Israel RJ. Methylnaltrexone treatment of opioid-induced constipation in patients with advanved illness. J Pain Symptom Manage 38(5):683-690, 2009 https://doi.org/10.1016/j.jpainsymman.2009.02.234
  47. Cho NH, Ryu BH. A study on Constipation. Korean J Orient Int Med 21(1):169-180, 2000
  48. Jeon CH, Cho CS. Postoperative adhesive small bowel obstruction treated using acupuncture and moxibustion: A case report. Korean J Orient Int Med 41(2):233-240, 2020 https://doi.org/10.22246/jikm.2020.41.2.233
  49. Lee JY, Moon YJ, Chae HN, Moon G, Kwon YM, Baek DG. Two case reports using herbal medicine for long-term chronic constipation patients who take laxatives. Korean J Orient Int Med 39(5):1052-1060, 2018 https://doi.org/10.22246/jikm.2018.39.5.1052
  50. Oh SD, Lim SM, Shin HS, Baek ET, Kim YT, Ra SY. The clinical review of bowel disorders following Parkinson's disease. Korean J Orient Int Med 22(4):735-742, 2001
  51. Kang YL, Kim YJ, Hwang CW. The clinical study on 45 cases of patients of constipation caused by C.V.A who were treated with Bo-Riu Enema. Korean J Orient Int Med 21(2):329-336, 2000